Capricor Therapeutics

Contributing Author

Recent Articles by Capricor Therapeutics

Jul-11	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy CAPR GlobeNewswire
Jun-24	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy CAPR GlobeNewswire
Jun-20	Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy CAPR GlobeNewswire
Jun-17	Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program CAPR GlobeNewswire
Jun-11	Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program CAPR GlobeNewswire
May-13	Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update CAPR GlobeNewswire
May-13	Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer CAPR GlobeNewswire
May-06	Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 CAPR GlobeNewswire
May-05	Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy CAPR GlobeNewswire